APAC

Alpha Fusion and Kobe Hospital launch At-211 Drug system

Alpha Fusion Inc. has announced a strategic collaboration with Kobe City Medical Center General Hospital (KCGH) to establish a domestic supply system for investigational drugs using Astatine-211 (At-211). This initiative represents a major milestone toward launching what is expected to be the world’s first company-sponsored clinical trial utilizing At-211, a promising radionuclide for targeted alpha therapy. Under the collaboration, KCGH has received approval from Japan’s Nuclear Regulation Authority to use At-211 and has begun technology transfer and test manufacturing of Alpha Fusion’s lead candidate, af-001, which targets differentiated thyroid cancer. The hospital’s radioactive investigational drug GMP manufacturing facility, renowned for its expertise in handling short-lived radionuclides for PET imaging, will play a central role in producing At-211-based investigational drugs under clinical-grade conditions. At-211 is regarded as one of the most…